Cerity Partners
RANI icon

Cerity Partners’s Rani Therapeutics RANI Stock Holding History

Cerity Partners’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14K Buy
19,090
+9,090
+91% +$11.6K ﹤0.01% 3194
2025
Q4 		$13.5K Hold
10,000
– – ﹤0.01% 2853
2025
Q3 		$5K Hold
10,000
– – ﹤0.01% 2738
2025
Q2 		$5.14K Hold
10,000
– – ﹤0.01% 2626
2025
Q1 		$12.6K Hold
10,000
– – ﹤0.01% 2459
2024
Q4 		$13.7K Hold
10,000
– – ﹤0.01% 2409
2024
Q3 		$21.6K Buy
+10,000
New +$28.7K ﹤0.01% 2509

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Cerity Partners's RANI Position: Q1 2026 in Review

Cerity Partners increased its Rani Therapeutics (RANI) stake by 91% in Q1 2026, buying an estimated $11.6K and bringing the position to 19,090 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

Cerity Partners first reported a position in RANI in Q3 2024 and has held it in 7 quarters since. The position peaked at $21.6K in Q3 2024. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Cerity Partners held 19,090 shares of Rani Therapeutics worth $14K as of Q1 2026.
  • Cerity Partners bought 9,090 Rani Therapeutics shares in Q1 2026, an estimated $11.6K.
  • Rani Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #3194 holding.
  • Cerity Partners first reported a position in Rani Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Cerity Partners's Rani Therapeutics position peaked at $21.6K in Q3 2024.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.